Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02060890 · ClinicalTrials.gov registry record

Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma

A clinical trial of Adult Glioblastoma, sponsored by University of California, San Francisco.

Completed
Registry status
20
Enrollment target
1
Study location

NCT02060890: Completed study of Adult Glioblastoma, sponsored by University of California, San Francisco.

NCT02060890 is a study of Adult Glioblastoma that has completed, run by University of California, San Francisco. The registered enrollment target is 20 participants, below the 42-participant average among 14 other Adult Glioblastoma trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02060890, a study of Adult Glioblastoma, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
20 participants
Enrollment target
1
Study location

Study Summary

This current study will use a new treatment approach based on each patient's tumor genomic profiling consisting of whole genome sequencing, exome analysis, and RNA sequencing as well as predictive modeling. This new treatment strategy has shown promising results in adult patients with other solid tumors.

Primary Outcome

To demonstrate feasibility, we would want the treatment recommendation to be fully complete within 35 calendar days in at least 85% of patients for which sufficient RNA and DNA is available.

Conditions Studied

Interventions

  • OTHER specialized tumor board recommendation

Study Locations (1)

California

  • University of California, San Francisco - San Francisco

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2014-08
Est. Completion 2017-05-10

What the finished NCT02060890 record still lists

NCT02060890 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 42-participant average among 14 other Adult Glioblastoma trials with a reported enrollment target (52% lower).

The record links to 1 condition, with Adult Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which specialized tumor board recommendation is the first listed.

NCT02060890 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT02060890 about?

NCT02060890 is a clinical study titled "Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma". This current study will use a new treatment approach based on each patient's tumor genomic profiling consisting of whole genome sequencing, exome analysis, and RNA sequencing as well as predictive modeling. This new treatment strategy has shown promising results in adult patients with other solid tu...

What is the current status of trial NCT02060890?

This trial is currently completed. The enrollment target is 20 participants. The study started on 2014-08. Estimated completion is 2017-05-10.

What conditions does trial NCT02060890 study?

This clinical trial studies the following conditions: Adult Glioblastoma.

What interventions are being tested in trial NCT02060890?

The interventions under investigation include: specialized tumor board recommendation (OTHER).

Who is sponsoring clinical trial NCT02060890?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02060890 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Adult Glioblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02060890's enrollment target sits among peer trials

20 10th of 14 higher than 5 of 14 other Adult Glioblastoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Adult Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02060890, the US trial registry maintained by the National Library of Medicine. NCT02060890 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.